Evolent Health price target lowered to $10 from $16 at BTIG

BTIG analyst David Larsen lowered the firm’s price target on Evolent Health (EVH) to $10 from $16 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 for Healthcare IT and Digital Health names. High medical trend is good for volume driven, fee-for-service stocks but unfavorable for value-based care stocks, and given macro challenges, the company may remain under pressure unless the management can offset investor concerns with favorable 2026 guidance and Q4 earnings, the analyst tells investors in a research note.